ArticleScientific reports2025
Structural insights into natural compound inhibitors of the human metapneumovirus nucleocapsid protein via molecular dynamics and free energy landscape analyses.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Subtractive Proteomics-Based Prioritization of Drug Targets in Enterococcus faecalis V583 and Structure-Based Identification of Plant-Derived Inhibitors Targeting Alanine Racemase: A High Priority Target.Molecular biotechnology · 2026Article
- Human Metapneumovirus Nucleocapsid Inhibitors Discovery for Targeting Viral Replication and Genome Encapsidation: An In Silico Approach.Journal of tropical medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Metapneumovirus (HMPV) is a major contributor to acute respiratory tract infections, particularly affecting children, the elderly, and immunocompromised individuals. Despite its global prevalence, no specific antiviral treatments or vaccines are available, highlighting the urgent need for effective therapeutic interventions. This study utilized a comprehensive computational drug discovery approach to identify potential inhibitors targeting the highly conserved nucleocapsid (N) protein of HMPV, a crucial component in viral replication and transcription. A virtual screening of 1,227 natural compounds from the NP-lib database was performed, identifying MOLPORT-001-742-110, MOLPORT-001-812-855, and MOLPORT-001-740-100 as the top candidates based on their docking scores and binding energies. The initial results were validated through re-docking, molecular interaction analysis, and molecular dynamics (MD) simulations. MOLPORT-001-742-110 demonstrated the highest stability with minimal deviations in Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) analyses, as well as a well-defined low-energy conformation in the Free Energy Landscape (FEL). Key hydrogen bonds and hydrophobic interactions were retained, reinforcing its strong binding affinity. Principal Component Analysis (PCA) and superimposition studies further supported the stability and adaptability of these compounds within the binding site. Comparative analyses with the control compound confirmed the superior inhibitory potential of the selected ligands, particularly MOLPORT-001-742-110. This study underscores the utility of computational approaches in identifying natural product-based inhibitors and provides a foundation for experimental validation and development of antiviral therapies against HMPV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.